HPV Associated Disorders Market Outlook 2031:
The global HPV associated disorders market size was valued at USD 19.45 Billion in 2022 and is projected to reach USD 28.90 Billion by 2031, expanding at a CAGR of 4.5% during the forecast period 2023 - 2031. The growth of the market is attributed to the rising penetration of treatment options and increasing prevalence of HPV-related diseases.
Human papillomavirus (HPV) is a group of virus responsible for causing HPV-related viral infections in human reproductive systems. HPV is a sexually-transmitted disease. There are many different types of HPV’s which causes life-threatening disorders and diseases.
There are more than 100 varieties of HPV are present out of which around 13 are cancerous or high risk and causes complication in patients. By using the activated gene-E6 or E7 the level of risk can be determined. HPV cause several diseases such as cervical cancer, anal cancer, genital warts, oropharyngeal cancer, anal intraepithelial neoplasia (AIN), cervical intraepithelial neoplasia (CIN), and vulvar cancer.
Increasing investment in R&D of cancer and favorable government initiatives are anticipated to help market for its growth. In 2010, Affordable Care act provides HPV testing, pap testing, and human papillomavirus vaccine for many patients.
Less awareness about treatment and diagnosis among people is affecting the market. But increasing expenditure on R&D of oncologic diseases is propelling the HPV associated disorder market. Also, there is huge unmet need of drugs with better clinical profile at low cost and suitable administration schedule.
Most HPV related disorder, particularly cervical cancer, in women develop over a period of 15 to 20 years with normal immunity, offering them a substantial frame for treatment and prevention form disease progression. In women with low or compromised immunity, it takes around 5 to 10 years only.
Also in women precancerous changes starts between 20 to 30 years of ages, even though in women the age of diagnosis of HPV related disorders is 50 years.
HPV Associated Disorders Market Trends, Drivers, Restraints, and Opportunities
- Rising prevalence of HPV Infections and growing investment in research and development of treatment are anticipated to drive the market growth.
- Technological advancement, growing demand of HPV co-testing, and rising adoption of targeted therapeutic systems are major factors boosting the market expansion in coming years.
- Increasing emergence of Point-of-care diagnostics and rapid HPV tests and rise in mRNA test for cervical cancer screening are projected to fuel the market growth over the forecast period.
- Lack of awareness among people about diagnosis & treatment of HPV associated diseases is major factor that can hamper the market expansion during the forecast period.
- Long- term negative effects due to therapies is anticipated to impede the market growth in coming years.
Scope of HPV Associated Disorders Market Report
The report on the global HPV associated disorders market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
HPV Associated Disorders Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Indications (Cervical Intraepithelial Neoplasia, Cervical Cancer, Anal Intraepithelial Neoplasia, Anal Cancer, Genital Warts, and Others), Therapies (Prevention and Treatment), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Merck & Co., Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Pfizer, Inc., Allergan plc., AstraZeneca plc., Biocon Ltd., and Eli Lilly and Company.
|
HPV Associated Disorders Market Segment Insights
Cervical cancer segment is projected to account for a large market share
Based on indications, the HPV associated disorders market is segmented into cervical intraepithelial neoplasia (CIN), cervical cancer, anal intraepithelial neoplasia (AIN), anal cancer, genital warts, and others.
The cervical cancer segment hold largest market share and is expected to account for a key share of the market during the forecast period owing to strong commercial performances of Avastin and Keytruda. The therapeutic landscape is alter by consequent penetration of biosimilars and Avastin’s near-term patent expiry.
On the other hand, the CIN segment is anticipated to expand at a rapid pace during the forecast period. Cervical intraepithelial neoplasia is a precancerous condition. Lack of proper diagnosis & treatment of CIN may results into cervical cancer.
Prevalence of disease is increasing because of unprotected sex, leading an unhealthy lifestyle, and people having multiple sex partners are expected to drive the segment growth.
Prevention segment is anticipated to register a substantial CAGR
On the basis of therapies, the HPV associated disorders market is divided into prevention and treatment. The therapeutic focus is shifted to prevention of disease which fuels the market of vaccine for human papillomavirus.
In market at present Cervarix and Gardasil are two vaccines present for HPV. Addition to this, in 2015, the FDA, approved Gardasil 9 which is an improvised and nonavalent version of Gardasil. This expansion of Gardasil gave a distinct clinical advantage over Cervarix.
The appearance of biosimilars and biologics brings a positive change in treatment segment with rising focus on targeted therapies. These targeted therapies were designed for counteracting and identifying specific disease cells. Label expansion of Avastin’s for cervical cancer introduced biologics and targeted therapies of HPV associated disorders.
Online pharmacies segment is expected to expand at a rapid pace
In terms of distribution channels, the market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to hold a key share of the market during the forecast period.
HPV related stock of products are preserved in hospital pharmacies. These products are associated to disorders, majorly for cervical & anal cancer and for outpatients and inpatients. In developing and underdeveloped economies increasing awareness among consumers and growing investment in healthcare infrastructure are expected to fuel the segment growth.
On the other hand, the online pharmacies segment is anticipated to expand at a rapid pace during the forecast period owing to accessibility, convenience in terms of prices and delivery, and user-friendly interfaces.
Also, they offers bundle pricing for cancer products or certain discounts on purchase of some products. The online pharmacies segment is driven by growing penetration of e-commerce.
North America is expected to dominate the market
On the basis of regions, the HPV associated disorders market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period.
The regional market growth can be attributed to huge commercial sales of biologics. Moreover, rise in expenditure of healthcare, local presence of key manufacturers, and favorable government initiatives are anticipated to drive the regional growth.
However, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years. Improvement in infrastructure of healthcare, growing awareness among consumers, swift economic development, and rising disposable income are major factors responsible for regional growth. Emerging economies such as India, China, and South Korea are anticipated to observe huge growth over the forecast period.
Segments
The global HPV associated disorders market has been segmented on the basis of
Indications
- Cervical Intraepithelial Neoplasia (CIN)
- Cervical Cancer
- Anal Intraepithelial Neoplasia (AIN)
- Anal Cancer
- Genital Warts
- Others
Therapies
Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
Key players competing in the HPV associated disorders market include Merck & Co., Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Pfizer, Inc., Allergan plc., AstraZeneca plc., Biocon Ltd., and Eli Lilly and Company. Major market players are focusing on several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
